Lexicon Pharmaceuticals (LXRX) Liabilities and Shareholders Equity (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $268.8 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 9.69% year-over-year to $268.8 million in Q1 2026; TTM through Mar 2026 was $885.3 million, a 31.4% decrease from a year earlier, with the FY2025 full-year figure at $185.0 million, down 38.01% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $268.8 million, up from $185.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for LXRX reached as high as $417.2 million in Q1 2024 and fell as low as $112.3 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $247.8 million across 5 years, with a median of $229.4 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity jumped 181.97% in 2023 and tumbled 39.58% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $194.3 million in 2022, then climbed by 18.08% to $229.4 million in 2023, then soared by 30.07% to $298.4 million in 2024, then slumped by 38.01% to $185.0 million in 2025, then surged by 45.32% to $268.8 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $268.8 million in Q1 2026, $185.0 million in Q4 2025, and $205.9 million in Q3 2025.